Related Experiment Video
Updated: Oct 23, 2025

07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
20.4K
TIL in Melanoma-Similar Approaches, Different Results, Unanswered Questions
1Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
Abstract:
Prior treatment with anti-PD-1 and/or BRAF-targeted therapies was associated with limited activity of tumor infiltrating lymphocytes (TIL) in metastatic melanoma. Recent insights into mechanisms of action for TIL and anti-PD-1 provide the foundation for understanding differences in outcomes in different trials or populations, and a roadmap for developing improved products. See related article by Seitter et al., p. 5289.

